CN115176162A - 新型冠状病毒抗原及其检测用途 - Google Patents
新型冠状病毒抗原及其检测用途 Download PDFInfo
- Publication number
- CN115176162A CN115176162A CN202180017343.7A CN202180017343A CN115176162A CN 115176162 A CN115176162 A CN 115176162A CN 202180017343 A CN202180017343 A CN 202180017343A CN 115176162 A CN115176162 A CN 115176162A
- Authority
- CN
- China
- Prior art keywords
- ncov
- subject
- sample
- detection
- reagent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000036639 antigens Human genes 0.000 title claims abstract description 38
- 108091007433 antigens Proteins 0.000 title claims abstract description 38
- 239000000427 antigen Substances 0.000 title claims abstract description 37
- 238000001514 detection method Methods 0.000 title claims description 156
- 241000711573 Coronaviridae Species 0.000 title claims description 71
- 238000000034 method Methods 0.000 claims abstract description 59
- 238000003556 assay Methods 0.000 claims abstract description 14
- 239000003153 chemical reaction reagent Substances 0.000 claims description 130
- 239000000523 sample Substances 0.000 claims description 108
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 60
- 229920001184 polypeptide Polymers 0.000 claims description 59
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 59
- 239000007787 solid Substances 0.000 claims description 50
- 108020001507 fusion proteins Proteins 0.000 claims description 47
- 102000037865 fusion proteins Human genes 0.000 claims description 47
- 208000015181 infectious disease Diseases 0.000 claims description 43
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 34
- 239000000872 buffer Substances 0.000 claims description 28
- 239000013642 negative control Substances 0.000 claims description 28
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 27
- 210000004369 blood Anatomy 0.000 claims description 23
- 239000008280 blood Substances 0.000 claims description 23
- 102000004190 Enzymes Human genes 0.000 claims description 22
- 108090000790 Enzymes Proteins 0.000 claims description 22
- 210000002966 serum Anatomy 0.000 claims description 22
- 239000012528 membrane Substances 0.000 claims description 21
- 229920001220 nitrocellulos Polymers 0.000 claims description 20
- 239000000020 Nitrocellulose Substances 0.000 claims description 19
- 239000011616 biotin Substances 0.000 claims description 18
- 229960002685 biotin Drugs 0.000 claims description 18
- 235000020958 biotin Nutrition 0.000 claims description 17
- 108090001008 Avidin Proteins 0.000 claims description 16
- 238000003018 immunoassay Methods 0.000 claims description 16
- 239000013641 positive control Substances 0.000 claims description 16
- 239000003795 chemical substances by application Substances 0.000 claims description 15
- 238000002965 ELISA Methods 0.000 claims description 14
- 210000004027 cell Anatomy 0.000 claims description 14
- 230000001900 immune effect Effects 0.000 claims description 14
- 102000039446 nucleic acids Human genes 0.000 claims description 14
- 108020004707 nucleic acids Proteins 0.000 claims description 14
- 150000007523 nucleic acids Chemical class 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 14
- 102000004169 proteins and genes Human genes 0.000 claims description 13
- 108090000623 proteins and genes Proteins 0.000 claims description 13
- 239000011324 bead Substances 0.000 claims description 11
- 239000003085 diluting agent Substances 0.000 claims description 11
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims description 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 8
- 210000002381 plasma Anatomy 0.000 claims description 8
- 239000012634 fragment Substances 0.000 claims description 7
- 238000003127 radioimmunoassay Methods 0.000 claims description 7
- -1 acridinium esters Chemical class 0.000 claims description 6
- 238000007792 addition Methods 0.000 claims description 6
- 238000012217 deletion Methods 0.000 claims description 6
- 230000037430 deletion Effects 0.000 claims description 6
- 238000006467 substitution reaction Methods 0.000 claims description 6
- 239000013598 vector Substances 0.000 claims description 6
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims description 5
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims description 5
- 230000000903 blocking effect Effects 0.000 claims description 5
- 239000007790 solid phase Substances 0.000 claims description 5
- 239000007850 fluorescent dye Substances 0.000 claims description 4
- 239000010931 gold Substances 0.000 claims description 3
- 229910052737 gold Inorganic materials 0.000 claims description 3
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 208000025721 COVID-19 Diseases 0.000 abstract description 18
- 241001678559 COVID-19 virus Species 0.000 abstract description 7
- 230000003612 virological effect Effects 0.000 abstract description 7
- 239000000243 solution Substances 0.000 description 46
- 239000011248 coating agent Substances 0.000 description 32
- 238000000576 coating method Methods 0.000 description 32
- 238000012360 testing method Methods 0.000 description 19
- 229940088598 enzyme Drugs 0.000 description 18
- 238000007789 sealing Methods 0.000 description 16
- 201000010099 disease Diseases 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 238000005406 washing Methods 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 12
- 241000700605 Viruses Species 0.000 description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 239000007853 buffer solution Substances 0.000 description 10
- 239000007788 liquid Substances 0.000 description 9
- 239000008055 phosphate buffer solution Substances 0.000 description 9
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 8
- 229910052782 aluminium Inorganic materials 0.000 description 8
- 239000011888 foil Substances 0.000 description 8
- 239000003365 glass fiber Substances 0.000 description 8
- 239000002994 raw material Substances 0.000 description 8
- 206010035664 Pneumonia Diseases 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 208000001528 Coronaviridae Infections Diseases 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- 238000002372 labelling Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 6
- 239000012089 stop solution Substances 0.000 description 6
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 5
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 5
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 5
- 206010037660 Pyrexia Diseases 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 125000005647 linker group Chemical group 0.000 description 5
- 239000008363 phosphate buffer Substances 0.000 description 5
- 208000035473 Communicable disease Diseases 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 241000872931 Myoporum sandwicense Species 0.000 description 4
- 238000012790 confirmation Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 230000007717 exclusion Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 150000002978 peroxides Chemical class 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 229940127002 anti-2019-nCov Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 2
- OBYNJKLOYWCXEP-UHFFFAOYSA-N 2-[3-(dimethylamino)-6-dimethylazaniumylidenexanthen-9-yl]-4-isothiocyanatobenzoate Chemical compound C=12C=CC(=[N+](C)C)C=C2OC2=CC(N(C)C)=CC=C2C=1C1=CC(N=C=S)=CC=C1C([O-])=O OBYNJKLOYWCXEP-UHFFFAOYSA-N 0.000 description 2
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 108010004729 Phycoerythrin Proteins 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 2
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000007605 air drying Methods 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 229960003677 chloroquine Drugs 0.000 description 2
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 2
- ZCIGNRJZKPOIKD-CQXVEOKZSA-N cobicistat Chemical compound S1C(C(C)C)=NC(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](CC=2C=CC=CC=2)NC(=O)OCC=2SC=NC=2)CC=2C=CC=CC=2)=C1 ZCIGNRJZKPOIKD-CQXVEOKZSA-N 0.000 description 2
- 229960002402 cobicistat Drugs 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 229960005107 darunavir Drugs 0.000 description 2
- CJBJHOAVZSMMDJ-HEXNFIEUSA-N darunavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1[C@@H]2CCO[C@@H]2OC1)C1=CC=CC=C1 CJBJHOAVZSMMDJ-HEXNFIEUSA-N 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 239000002274 desiccant Substances 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- ZCGNOVWYSGBHAU-UHFFFAOYSA-N favipiravir Chemical compound NC(=O)C1=NC(F)=CNC1=O ZCGNOVWYSGBHAU-UHFFFAOYSA-N 0.000 description 2
- 229950008454 favipiravir Drugs 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 2
- 229960004171 hydroxychloroquine Drugs 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 229960004525 lopinavir Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 229960000329 ribavirin Drugs 0.000 description 2
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 2
- 229960000311 ritonavir Drugs 0.000 description 2
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- KCFYEAOKVJSACF-UHFFFAOYSA-N umifenovir Chemical compound CN1C2=CC(Br)=C(O)C(CN(C)C)=C2C(C(=O)OCC)=C1CSC1=CC=CC=C1 KCFYEAOKVJSACF-UHFFFAOYSA-N 0.000 description 2
- 229960004626 umifenovir Drugs 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 208000010444 Acidosis Diseases 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 102100031673 Corneodesmosin Human genes 0.000 description 1
- 101710139375 Corneodesmosin Proteins 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010027417 Metabolic acidosis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010028748 Nasal obstruction Diseases 0.000 description 1
- 241001292005 Nidovirales Species 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 101710147732 Small envelope protein Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 244000144980 herd Species 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000003317 immunochromatography Methods 0.000 description 1
- 238000010324 immunological assay Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 208000010753 nasal discharge Diseases 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/165—Coronaviridae, e.g. avian infectious bronchitis virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
提供了对2019‑nCoV特异性的IgM抗体和总抗体的方法以及确定受试者是否患有2019‑nCoV感染的方法，以及用于上述检测的病毒抗原及试剂盒。
Description
PCT国内申请，说明书已公开。
Claims (22)
- PCT国内申请，权利要求书已公开。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010131338.6A CN113321715B (zh) | 2020-02-28 | 2020-02-28 | 新型冠状病毒抗原及其检测用途 |
| CN2020101313386 | 2020-02-28 | ||
| PCT/CN2021/072392 WO2021169664A1 (zh) | 2020-02-28 | 2021-01-18 | 新型冠状病毒抗原及其检测用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115176162A true CN115176162A (zh) | 2022-10-11 |
| CN115176162B CN115176162B (zh) | 2024-04-05 |
Family
ID=77412861
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010131338.6A Active CN113321715B (zh) | 2020-02-28 | 2020-02-28 | 新型冠状病毒抗原及其检测用途 |
| CN202180017343.7A Active CN115176162B (zh) | 2020-02-28 | 2021-01-18 | 新型冠状病毒抗原及其检测用途 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010131338.6A Active CN113321715B (zh) | 2020-02-28 | 2020-02-28 | 新型冠状病毒抗原及其检测用途 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20230358757A1 (zh) |
| EP (1) | EP4113121A4 (zh) |
| CN (2) | CN113321715B (zh) |
| WO (1) | WO2021169664A1 (zh) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114034871A (zh) * | 2021-11-16 | 2022-02-11 | 江苏晶红生物医药科技股份有限公司 | 一种新型冠状病毒中和抗体检测试剂盒及其制备方法 |
| CN114107019B (zh) * | 2021-11-25 | 2024-01-12 | 复旦大学 | 一种同时检测核酸和蛋白质的微流控芯片、检测方法及用途 |
| CN115629145A (zh) * | 2022-12-07 | 2023-01-20 | 北京和合医学诊断技术股份有限公司 | 一种同时检测7种抗新冠病毒药物含量的方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1806175A (zh) * | 2003-06-10 | 2006-07-19 | 新加坡科技研究局 | 诊断sars冠状病毒感染的方法 |
| US20100035231A1 (en) * | 2006-05-11 | 2010-02-11 | National Environment Agency | Antigen capture anti-dengue iga elisa (aca-elisa) for the detection of a flavivirus specific antibody |
| EP3530668A1 (en) * | 2018-02-22 | 2019-08-28 | Euroimmun Medizinische Labordiagnostika AG | A novel assay for the diagnosis of viral infections |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2569142A1 (en) * | 2004-06-02 | 2005-12-22 | New York Blood Center | Sars vaccines and methods to produce highly potent antibodies |
| US20100266620A1 (en) * | 2006-01-20 | 2010-10-21 | Le Sun | Immunoconjugates for treatment of infectious diseases |
| CN104447986B (zh) * | 2014-12-23 | 2017-12-29 | 中国科学院微生物研究所 | 一种中东呼吸综合征冠状病毒中和抗体及其制备方法 |
| GB201804243D0 (en) * | 2018-03-16 | 2018-05-02 | Liverpool School Tropical Medicine | Hinge sequences |
| CN113292649B (zh) * | 2020-02-24 | 2022-08-12 | 中国科学院微生物研究所 | 新型冠状病毒的人源单克隆抗体及其应用 |
| CN111393532B (zh) * | 2020-02-26 | 2021-10-12 | 北京丹大生物技术有限公司 | 新型冠状病毒优势表位融合蛋白、诊断试剂及应用 |
| CN111239392B (zh) * | 2020-02-26 | 2023-04-21 | 浙江诺迦生物科技有限公司 | 一种新型冠状病毒肺炎(covid-19)血清学诊断试剂盒 |
-
2020
- 2020-02-28 CN CN202010131338.6A patent/CN113321715B/zh active Active
-
2021
- 2021-01-18 US US17/802,290 patent/US20230358757A1/en active Pending
- 2021-01-18 WO PCT/CN2021/072392 patent/WO2021169664A1/zh unknown
- 2021-01-18 CN CN202180017343.7A patent/CN115176162B/zh active Active
- 2021-01-18 EP EP21760161.6A patent/EP4113121A4/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1806175A (zh) * | 2003-06-10 | 2006-07-19 | 新加坡科技研究局 | 诊断sars冠状病毒感染的方法 |
| US20100035231A1 (en) * | 2006-05-11 | 2010-02-11 | National Environment Agency | Antigen capture anti-dengue iga elisa (aca-elisa) for the detection of a flavivirus specific antibody |
| EP3530668A1 (en) * | 2018-02-22 | 2019-08-28 | Euroimmun Medizinische Labordiagnostika AG | A novel assay for the diagnosis of viral infections |
Non-Patent Citations (2)
| Title |
|---|
| LAN，J.等: "Crystal structure of the 2019-nCoV spike receptor-binding domain bound with the ACE2 receptor", BIORXIV, pages 4 * |
| WU，F. 等: "surface glycoprotein [Severe acute respiratory syndrome coronavirus 2]", YP_009724390 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115176162B (zh) | 2024-04-05 |
| WO2021169664A1 (zh) | 2021-09-02 |
| CN113321715B (zh) | 2023-02-17 |
| EP4113121A4 (en) | 2024-03-27 |
| EP4113121A1 (en) | 2023-01-04 |
| US20230358757A1 (en) | 2023-11-09 |
| CN113321715A (zh) | 2021-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2021179371A1 (zh) | 新冠病毒n-s优势表位融合蛋白、制备方法、应用，及表达蛋白、微生物、应用，试剂盒 | |
| US20230296601A1 (en) | Novel coronavirus antibody detection kit based on magnetic particle chemiluminescence | |
| WO2021232712A1 (zh) | 新型冠状病毒igm/igg磁微粒化学发光免疫检测试剂盒 | |
| CN115176162B (zh) | 新型冠状病毒抗原及其检测用途 | |
| EP2063270A1 (en) | Rapid diagnosis method specific to avian influenza virus | |
| CN112964884B (zh) | 一种诊断标志物及其在covid-19诊断及冠状病毒既往感染检测中的应用 | |
| WO2006081718A1 (fr) | Kit et procede de detection d'anticorps anti-virus de l'hepatite c (vhc) | |
| WO2021227994A1 (zh) | 一种采用血管紧张素转化酶ii（ace2）检测冠状病毒的方法 | |
| WO2022193980A1 (zh) | 针对新型冠状病毒核衣壳蛋白的抗体或其抗原结合片段及其应用 | |
| US11740240B2 (en) | Immunoassay for SARS-CoV-2 neutralizing antibodies and materials therefor | |
| WO2021232713A1 (zh) | 一种新型冠状病毒IgG抗体的酶联免疫法检测试剂盒 | |
| CN111474348B (zh) | 一种新型冠状病毒的检测试剂盒以及检测方法 | |
| US20210349105A1 (en) | Sars-cov-2 immunoassay and materials therefor | |
| WO2021232714A1 (zh) | 一种新型冠状病毒IgM抗体的酶联免疫法检测试剂盒 | |
| CN110818800A (zh) | 一种通过构建桥连复合物间接检测目的分析物的检测方法 | |
| CN105510580B (zh) | 一种检测发热伴血小板减少综合征病毒核衣壳蛋白特异性抗体的多肽‑酶联免疫吸附试剂盒 | |
| CA3125206A1 (en) | Specific monoclonal antibodies for the hepatitis pb2 of the influenza humana (flu), nucleic acid sequences; method and kit of inprol produced by flu | |
| KR101032956B1 (ko) | 수청바이러스 유래 뉴클레오캡시드 단백질을 이용하여 신증후출혈열 특이 ＩｇＭ과 ＩｇＧ를 검출하는 신속 진단 키트 | |
| CN113252911A (zh) | SARS-CoV-2中和抗体的检测试剂盒及其应用 | |
| KR20210144562A (ko) | Covid-19의 급성 호흡기 증후군 바이오마커 검출용 조성물 및 키트 | |
| CN105606816B (zh) | 一种检测发热伴血小板减少综合征病毒包膜糖蛋白特异性抗体的多肽‑酶联免疫吸附试剂盒 | |
| CN113156118B (zh) | 一种诊断标志物及其在covid-19诊断及冠状病毒既往感染检测中的应用 | |
| CN109613239B (zh) | A群轮状病毒检测试纸 | |
| CN110531079B (zh) | 新城疫病毒抗体检测试剂盒 | |
| CN112946297A (zh) | 一种解脲支原体感染的诊断标物及其对应的检测试剂盒的制备方法与应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |